Ceribell adds quantitative EEG trends: Its newly cleared software presents alpha-delta ratio, relative alpha, burst suppression, and amplitude-integrated EEG trends for clinicians monitoring patients across age groups.

A closer look at SmartVertigo: The portable, prescription-use system records eye movements during vestibular assessment. Its July clearance leaves diagnosis and treatment decisions with the clinician.

CLEAR moves toward U.S. use: Insera’s previously announced, FDA-cleared system offers cyclical, uniform, and blood saver aspiration modes for fresh, soft clots in peripheral vessels.

What we’re watching next: Deployment dates, clinical workflow studies, and evidence that these tools improve decisions rather than simply make more data available.

Brain activity trends: Alpha-delta ratio and relative alpha trending may help clinicians identify changes associated with brain distress or reduced blood flow in high-risk patients, including those with subarachnoid hemorrhage. A trend is a prompt for clinical assessment, not a stand-alone diagnosis of ischemia.

Sedation monitoring: Burst suppression monitoring gives care teams another view of brain activity when managing severe ongoing seizures or brain swelling and adjusting treatment.

Across age groups: Amplitude-integrated EEG supports simplified, longer-term monitoring, including neonatal assessment. The clearance has no age restriction, and Ceribell expects to deliver the features through an automatic update in the first half of 2027.

Portable eye-movement recording: Clinicians can use the headset during familiar positional maneuvers and review recorded horizontal, vertical, and torsional eye movements.

Defined clinical role: The cleared device records, tracks, stores, and displays eye movements. Its stated indication says it does not provide a diagnosis or diagnostic recommendation; a licensed clinician interprets the findings.

Evidence still developing: VertigoDx says SmartVertigo is being evaluated in an IRB clinical study. Claims that it can rule out cerebellar stroke or safely replace emergency neuroimaging require evidence beyond this clearance.

Intended use: CLEAR is designed to remove fresh, soft emboli and thrombi from vessels of the peripheral arterial and venous systems. The system includes a pump and compatible single-use catheters and other disposables.

Selectable aspiration: Operators can choose cyclical, uniform, or blood saver modes. Insera also reports that the platform holds a CE mark in the European Union.

Performance question: The clearance was supported by safety and performance testing. It does not establish that CLEAR improves first-pass success, reduces blood loss in patients, or outperforms continuous aspiration in comparative clinical care.

Ceribell’s rollout: Whether the planned first-half 2027 software update is delivered on schedule and how neuro-ICUs incorporate the new trends into review and escalation protocols.

SmartVertigo validation: Whether prospective studies establish where portable eye-movement recording improves assessment, without treating the device as a stroke rule-out test.

CLEAR’s clinical performance: Comparative data on clot removal, procedural time, and blood loss across aspiration modes and existing devices.

Basecamp Research: A $140 million Series C, led by S32, to develop its EDEN biological models and advance AI-designed therapeutics toward clinical development. The round was announced September 23 and also appeared in our recent coverage.

Tiny Health: A $33 million Series B, led by B Capital. The company says it has served nearly 200,000 customers and is introducing TinyAI, built on a dataset of nearly 200,000 microbiome profiles. Its intended personalized guidance should not be presented as a validated pediatric treatment decision engine.

Basalt Health: A $20 million Series A, led by NEA, to expand its post-acute admissions platform. Basalt says it is live at Lifepoint Health and plans to scale across 62 ScionHealth hospitals by the end of 2026; that rollout is a target, not a completed deployment.

Frontiers Health 2026: October 20–21 | Berlin, Germany. A digital health gathering for founders, clinicians, investors, and health industry leaders.

HLTH USA 2026: November 15–18 | Las Vegas, NV. Healthcare leaders, payers, providers, and technology companies meet across the four-day program.

RSNA 2026: November 29–December 3 | Chicago, IL. The radiology scientific assembly and annual meeting at McCormick Place.

Ceribell EEG Analysis Software: Newly cleared quantitative EEG trends for longitudinal brain monitoring; Ceribell expects the update in the first half of 2027.

SmartVertigo Vestibular Assessment System: A portable way for clinicians to record and review eye movements during vestibular assessment; it does not issue diagnoses.

TinyAI: Tiny Health’s newly introduced system for generating personalized guidance from microbiome results. Clinical benefit remains to be established.

VertigoDx: Developing portable vestibular assessment tools for clinician-supervised use.

Insera Therapeutics: Bringing selectable aspiration modes to peripheral mechanical thrombectomy.

Tiny Health: Expanding microbiome testing, research access, and personalized interpretation following its Series B.

Decentralizing the Neuro-ICU: How Quantitative EEG Could Change Bedside Triage Economics
What easier access to EEG trends may mean for review time, specialist workflows, and treatment decisions—and what must be measured after Ceribell’s update reaches hospitals.

Mobile Optical Diagnostics: Where SmartVertigo Fits in the Emergency Vertigo Workup
The potential value of portable eye-movement recording, the limits of its cleared indication, and the evidence needed before changing imaging or referral pathways.

Cyclical Mechanics vs. Static Vacuum: The Next Question in Endovascular Thrombectomy
How CLEAR’s aspiration modes differ and which comparative clinical results would matter to interventionists and hospital buyers.